AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $7.73 million. The enterprise value is $1.69 million.
| Market Cap | 7.73M |
| Enterprise Value | 1.69M |
Important Dates
The last earnings date was Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 30.44 million shares outstanding. The number of shares has increased by 894.51% in one year.
| Current Share Class | 30.44M |
| Shares Outstanding | 30.44M |
| Shares Change (YoY) | +894.51% |
| Shares Change (QoQ) | +293.40% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 3.77% |
| Float | 27.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 82.27 |
| Forward PS | n/a |
| PB Ratio | 0.97 |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 0.51.
| Current Ratio | 2.11 |
| Quick Ratio | 2.01 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.52 |
Financial Efficiency
Return on equity (ROE) is -2,382.30% and return on invested capital (ROIC) is -175.70%.
| Return on Equity (ROE) | -2,382.30% |
| Return on Assets (ROA) | -82.58% |
| Return on Invested Capital (ROIC) | -175.70% |
| Return on Capital Employed (ROCE) | -143.07% |
| Weighted Average Cost of Capital (WACC) | 15.07% |
| Revenue Per Employee | $4,524 |
| Profits Per Employee | -$679,524 |
| Employee Count | 21 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.29% in the last 52 weeks. The beta is 1.19, so AIM ImmunoTech's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -90.29% |
| 50-Day Moving Average | 0.29 |
| 200-Day Moving Average | 0.77 |
| Relative Strength Index (RSI) | 47.13 |
| Average Volume (20 Days) | 1,480,061 |
Short Selling Information
The latest short interest is 913,892, so 3.00% of the outstanding shares have been sold short.
| Short Interest | 913,892 |
| Short Previous Month | 2.20M |
| Short % of Shares Out | 3.00% |
| Short % of Float | 3.30% |
| Short Ratio (days to cover) | 1.29 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $95,000 and -$14.27 million in losses. Loss per share was -$2.14.
| Revenue | 95,000 |
| Gross Profit | -22,000 |
| Operating Income | -11.14M |
| Pretax Income | -14.27M |
| Net Income | -14.27M |
| EBITDA | -10.73M |
| EBIT | -11.14M |
| Loss Per Share | -$2.14 |
Balance Sheet
The company has $9.96 million in cash and $3.92 million in debt, with a net cash position of $6.04 million or $0.20 per share.
| Cash & Cash Equivalents | 9.96M |
| Total Debt | 3.92M |
| Net Cash | 6.04M |
| Net Cash Per Share | $0.20 |
| Equity (Book Value) | 7.74M |
| Book Value Per Share | 0.27 |
| Working Capital | 5.49M |
Cash Flow
| Operating Cash Flow | -14.37M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 404,000 |
| Net Borrowing | 1.02M |
| Free Cash Flow | -14.37M |
| FCF Per Share | -$0.47 |
Margins
| Gross Margin | -23.16% |
| Operating Margin | -11,724.21% |
| Pretax Margin | -15,021.05% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -894.51% |
| Shareholder Yield | -894.51% |
| Earnings Yield | -182.57% |
| FCF Yield | -183.90% |
Analyst Forecast
The average price target for AIM ImmunoTech is $4.25, which is 1,573.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.25 |
| Price Target Difference | 1,573.23% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 9, 2026. It was a forward split with a ratio of 1.001:1.
| Last Split Date | Jan 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.001:1 |
Scores
AIM ImmunoTech has an Altman Z-Score of -50.91 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -50.91 |
| Piotroski F-Score | 1 |